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Background: Polymer-free drug-eluting stents (DES) may overcome the shortcomings of polymer-based
DES. The aim of this study was to examine the effect of the polymer-free TiO2 ﬁlm-coated stent with
abciximab or alpha lipoic acid in a porcine coronary overstretch restenosis model.
Methods: Pigs were randomized into four groups in which the coronary arteries (24 pigs, 48 coronaries in
each group) had TiO2 ﬁlm-coated stent with abciximab (TCA, n=12), TiO2 ﬁlm-coated stent with alpha
lipoic acid (TCALA, n=12), biolimus A9-eluting stents with biodegradable polymer (BES, n=12), and TiO2
ﬁlm-coated stent (TCstent, n=12). Histopathologic analysis was performed at 28 days after stenting.
Results: There was no signiﬁcant difference in the injury score and internal elastic lamina (IEL) among
the four groups. There were signiﬁcant differences in the lumen area, neointima area, percent area
stenosis, ﬁbrin score, and inﬂammation score among the four groups [2.7±1.0mm2, 2.6±0.94mm2,
48.9±16.25%, 1.0 (range 0.0–3.0), 1.0 (range 0.0–2.0) in TCA stent group vs. 2.7±1.24mm2,
2.9±0.83mm2, 53.5±17.19%, 1.0 (range 0.0–2.0), 1.0 (range 0.0–2.0) in TCALA stent group vs.
2.7±1.30mm2, 2.6±1.06mm2, 50.1±23.20%, 2.0 (range 1.0–3.0), 2.0 (range 1.0–3.0) in BES group vs.
2 21.7±0.63mm , 3.3±0.58mm , 60.2±10.12%, 0.5 (range 0.0–2.0), 1.0 (range 0.0–2.0) in TC stent group,
respectively].
Conclusion: TCA and TCALA are more effective to reduce neointimal hyperplasia compared to TC. More-
over, ﬁbrinand inﬂammationscoresare signiﬁcantly lower inTCAandTCALA thanBES inporcinecoronary
restenosis model.
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914-5087/© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
Introduction
In recent years, drug-eluting stents (DES) have emerged as
the preferred treatment for coronary artery disease and the use
of DES has increased signiﬁcantly. Current DES treatment for
coronary artery disease is promising, but it has the drawback of
late in-stent thrombosis and delayed re-endothelialization [1].
These can be related to polymers, which were used in bare metal
stent coating [2–4]. Therefore, we developed a novel and efﬁcient
drug-combining technology onto a TiO2 ﬁlmwithout the polymers
to reduce the problems of the polymer-based DES [5].
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Abciximab blocks the ﬁnal common pathway of platelet aggre-
ation [6]. Abciximab reacts to V3 receptor of vascular smooth
uscle cell and to Mac-1 of macrophage and inhibits prolifera-
ion of vascular smooth muscle cells and inﬂammatory reaction
7–9]. Our previous study showed that abciximab-coated stent
educed stent restenosis by inhibition of cell proliferation, inﬂam-
ation reaction, and extracellularmatrix synthesis comparedwith
are-metal stent in a porcine coronary restenosis model [10,11].
lpha lipoic acid (ALA) is a potent antioxidant, which has a direct
ree-radical scavenger effect [12,13]. Moreover, ALA inhibits the
nﬂammatory reaction and suppresses neointima formation after
tenting [14]. Our previous study showed that ALA-coated stent
educes in-stent restenosis in a porcine coronary restenosis model
15].
Biolimus A9-eluting stents (BES, Biomatrix, Biosensors Inter-
entional Technologies Pte Ltd., Singapore), whichwere developed
s a third-generation DES, contain a biodegradable polymer with
iolimus A9.
The objective of the present study was to evaluate the effect
f polymer-free TiO2 ﬁlm-coated stent with abciximab or ALA in a
orcine coronary restenosis model.
ethods
nimal preparation and stent implantation
The animal study was approved by the Ethics Committee
f Chonnam National University Medical School and Chonnam
ational University Hospital (CNU IACUC-H-2012-24), and con-
ormed to the Guide for the Care and Use of Laboratory Animals
ublished by the US National Institutes of Health (NIH Publica-
ion No. 85-23, revised 1996). Study animals were castrated male
igs weighing 20–25kg. To prevent acute thrombosis after stent-
ng, premedication with aspirin 100mg and clopidogrel 75mg
er day was given for 5 days before the procedure. On the
rocedure day, pigs were anesthetized with zolazepam and tile-
amine (2.5mg/kg, Zoletil50®, Virbac, Caros, France), xylazine
3mg/kg, Rompun®, Bayer AG, Leverkusen, Germany), and azap-
rone (6mg/kg, Stresnil®, Janssen-Cilag, Neuss, Germany). They
eceived supplemental oxygen continuously through an oxygen
ask. Subcutaneous 2% lidocaine at the cut-down site was admin-
stered, left carotid artery was surgically exposed, and a 7-French
heath was inserted.
Continuous hemodynamic and surface electrocardiographic
onitoringweremaintained throughout the procedure. Then 5000
nits of heparin were administered intravenously as a bolus prior
o the procedure, the target coronary artery was engaged using
tandard 7-F guide catheters and control angiograms of both coro-
ary arteries were performed using nonionic contrast agent in two
rthogonal views.
The stent was deployed by inﬂating the balloon and the result-
ng stent-to-artery ratio was 1.3:1. Coronary angiograms were
btained immediately after stent implantation. Then, all equip-
ents were removed and the carotid artery was ligated.
Four weeks after stenting, the animals underwent follow-up
ngiography in the same orthogonal views before deathwith 20ml
f potassium chloride intracoronary injection.
The hearts were removed, and the coronary arteries were
ressure-perfusion ﬁxed at 110mmHg in 10% neutral buffered for-
alin overnight. Eachof the 10 stented arterieswas step-sectioned,
rocessed routinely for light microscopy, and stained for histolog-
cal analysis in four groups. And each of the 2 specimens of four
roups was analyzed by both scanning electron microscopy (SEM)
nd micro-computerized tomography (M-CT).logy 64 (2014) 409–418
Study groups
The pigs were randomly divided into 4 groups: group 1 (TiO2
ﬁlm-coated stent with abciximab, TCA stent, 3.0mm×16mm,
n=12); group 2 (TiO2 ﬁlm-coated stent with ALA, TCALA stent,
3.0mm×16mm, n=12); group 3 (biolimus A9-eluting stents with
biodegradable polymer, BES, 3.0mm×18mm, n=12); and group 4
(TiO2 ﬁlm-coated stent, TC stent, 3.0mm×16mm, n=12).
A total of 24 pigs were used in this study (24 pigs, 48 coro-
nary arteries, 12 coronary arteries in each group). A TCA stent, a
TCALA stent, a BES, and a TC stent were implanted in the left ante-
rior descending artery and left circumﬂex artery by randomized
manner in a pig.
Preparation of TiO2 ﬁlm-coated stent with abciximab and ALA
A TiO2 thin ﬁlm was deposited onto a bare metal stent
(3.0mm×16mm, cobalt–chromium alloy) by the plasma-
enhanced chemical vapor deposition (PECVD) process and its
potential as a drug-combining matrix was investigated. When
deposited at a discharge power of 5W, the ﬁlm showed a highly
smooth surfacewith a surface roughness of 9.4nm,mechanical sta-
bility with good adhesion, and good blood compatibility. The ﬁlm
was surface-modiﬁed with water plasma to introduce hydroxyl
groups on the TiO2 surface. Then, drugs could be chemically
grafted to the modiﬁed surface through the formation of ester
bonds between hydroxyl groups on the modiﬁed TiO2 ﬁlm and
carboxyl groups in the drugs. When abciximab or ALA was grafted
onto the TiO2-deposited and surface-modiﬁed stents, the grafted
amount was measured to be 106.1g for ALA and 32.5g for
abciximab on average. In the in vitro drug-release test, abciximab
was released continuously for 4 weeks but ALA showed a burst
release within 6 days [5].
Histopathologic, scanning electron microscopy, micro-computed
tomography, and immunohistochemistry analyses
Histopathologic evaluation of each artery was performed by
an experienced cardiovascular pathologist. The specimens were
embedded and sections of 50–100m thickness were obtained
at about 1mm apart and stained with hematoxylin–eosin (Fig. 1),
Verhoeff’s Van Gieson (Fig. 2), and Carstairs’ (Fig. 3) for histolog-
ical analysis. Measurements of the histopathologic sections were
performed using a calibrated microscope, digital video imaging
system, and microcomputer program (Visus 2000 Visual Image
Analysis System, IMT Tech, CA, USA). Bordersweremanually traced
for lumen area, area circumscribed by the internal elastic lamina,
and the innermost border of the external elastic lamina (exter-
nal elastic lamina area). Morphometric analysis of the neointimal
area for a given vessel was calculated as the measured internal
elastic lamina area minus lumen area. The measurements were
made on ﬁve cross-sections from the proximal and distal ends
and the three midpoints of each stented segment. Histopatho-
logic stenosiswascalculatedas100× [1− (lesion lumenarea/lesion
internal elastic lamina area)] [16]. The harvested stent specimen
was stored in formaldehyde solution. A 1.5-ml Eppendorf tube
was ﬁlled with clay, and the clay was turned with a V shape to
hold the stent during contrast agent staining. The stents were
taken from the solution and placed vertically in the V-shaped
opening in the clay. Each stent had to be ﬁxed with the clay
such that there was no movement of the stent inside the Eppen-
dorf tube. The contrast agent used was omnihexol. One milliliter
of the contrast agent was taken in a 5-ml syringe and injected
through the opening at the center of the stent. The stent was
incubated with contrast agent overnight and subjected to M-
CT imaging [17]. After performing the M-CT analysis, for SEM,
K.S. Lim et al. / Journal of Cardiology 64 (2014) 409–418 411
Fig. 1. Representative images of hematoxylin and eosin staining at 4 weeks after stenting. Specimen TCA stent implanted (A: 20×), TCALA stent implanted (B: 20×), BES
implanted (C: 20×) and TC stent implanted (D: 20×). Immunohistochemistry using anti-smoothmuscle actin monoclonal antibody in neointimal proliferation. Immunoﬂuo-
r cells,
w iolimu
( rred to
t
s
d
oescence staining showing expression of -smoothmuscle actin (bright red positive
ith abciximab; TCALA stent, TiO2 ﬁlm-coated stent with alpha lipoic acid; BES, b
For interpretation of the references to color in this ﬁgure legend, the reader is refehe longitudinally cut sections were rinsed in three changes of
odium phosphate, ﬁxed in 1% osmium tetroxide, and rinsed in
istilled water. The specimens were dehydrated in a graded series
f alcohols, critically point dried, placed in a vacuum coater, and200×, A-1 =TCA, B-1=TCALA, C-1=BES, D-1=TC). TCA stent, TiO2 ﬁlm-coated stent
s A9-eluting stent with biodegradable polymer; TC stent, TiO2 ﬁlm-coated stent.
the web version of the article.)coated with 30–40nm gold. Luminal surfaces were photographed
at 100×. Photographs were digitized, and the strut coverage was
observed [18]. Immunohistochemistry (IHC) was conducted by
standard procedures as previously described [19]. Monoclonal
412 K.S. Lim et al. / Journal of Cardiology 64 (2014) 409–418
Fig. 2. Representative images of Verhoeff’s Van Gieson staining of elastic ﬁber in TCA stent implanted (A: 20×, A-1: 200×), TCALA stent implanted (B: 20×, B-1: 200×), BES
implanted (C: 20×, C-1: 200×), and TC stent implanted (D: 20×, D-1: 200×). TCA stent, TiO2 ﬁlm-coated stent with abciximab; TCALA stent, TiO2 ﬁlm-coated stent with alpha
lipoic acid; BES, biolimus A9-eluting stent with biodegradable polymer; TC stent, TiO2 ﬁlm-coated stent.
a
S
b
w
fnti-actin (alpha-smooth muscle antibody produced in mouse,
igma–Aldrich, St. Louis, MO, USA) was used. IHC was analyzed
y ﬂuorescence microscopy and digital photography. All results
ere interpreted by two independent pathologists in a blinded
ashion.Evaluation of arterial injuryArterial injury at each strut sitewasdeterminedby the anatomic
structures penetrated by each strut. A numeric value was assigned,
as previously described by Schwartz et al. [16]: 0 =no injury;
K.S. Lim et al. / Journal of Cardiology 64 (2014) 409–418 413
Fig. 3. The Carstair ﬁbrin stain of the low- and high-power ﬁelds (magnitude, 20×, 200×) of ﬁbrin inﬁltration in TCA stent implanted (A, A-1), TCALA stent implanted
( t impl
ﬁ radab
1
m
a
l
sB, B-1), BES implanted (C, C-1: black arrow indicates ﬁbrin deposition) and TC sten
lm-coated stent with alpha lipoic acid; BES, biolimus A9-eluting stent with biodeg
=break in the internal elastic membrane; 2 =perforation of the
edia; 3 =perforation of the external elastic membrane to the
dventitia. The average injury score for each segment was calcu-
ated by dividing the sum of injury scores by the total number of
truts at the examined section.anted (D, D-1). TCA stent, TiO2 ﬁlm-coated stent with abciximab; TCALA stent, TiO2
le polymer; TC stent, TiO2 ﬁlm-coated stent.
Evaluation of inﬂammation scores, neointimal reaction, and ﬁbrin
scoreWith regard to the inﬂammation score for each individ-
ual strut, the grading was as follows: 0 =no inﬂammatory cells
surrounding the strut; 1 = light, noncircumferential lymphohisti-
4 Cardio
o
c
3
s
l
s
d
0
S
m
T
t
o
g
a
t
i
s
R
A
A
1
d
i
s
H
g
i
b
t
[
T
1
i
s
T
n
g
i
i
2
g
a
T
i
i
v
s
0
g
T14 K.S. Lim et al. / Journal of
cytic inﬁltrate surrounding strut; 2 = localized, moderate to dense
ellular aggregate surrounding the strut noncircumferentially;
= circumferential dense lymphohistiocytic cell inﬁltration of the
trut. The inﬂammation score for each cross section was calcu-
ated by dividing the sum of the individual inﬂammation score
by the total number of struts at the examined section [20]. Ordinal
ata for ﬁbrin were collected on each stent section using a scale of
–3 as previously reported [21].
tatistical analysis
Statistical analysis was performed with the aid of the com-
ercially available software (SPSS Version 15, Chicago, IL, USA).
he data were presented as mean value± SD. Unpaired Student’s
test was used for the comparison of each stent group. Analysis
f variance (ANOVA) was used for comparisons of the four stent
roups. Ordinal measurements such as injury score, ﬁbrin score,
nd inﬂammation score were analyzed using the Kruskal–Wallis
est. Non-parametric results were presented as median and
nterquartile range. A value of p<0.05 was considered statistically
igniﬁcant.
esults
nalysis after stenting
Two stents were placed for two coronary arteries per swine.
total of 48 stents, including 12 TCA stents, 12 TCALA stents,
2 BESs, and 12 TC stents, were placed in the proximal left anterior
escending and proximal circumﬂex artery for 24 swine. Mortal-
ty for this study was zero. There was no signiﬁcant difference in
tent-to-artery ratio among the four stent groups.
istopathologic and immunohistochemistry analyses among 4
roups
To conﬁrm the characteristics of smooth muscle cells (SMCs)
n neointima proliferation tissue, the stented arteries were stained
y anti-SMC antibody. SMCs were major components of neointima
issue after stenting in all groups (Fig. 1).
There were no signiﬁcant differences in the injury score
2.0 (range 1.0–3.0) in TCA stent group vs. 2.0 (range 1.0–3.0) in
CALA stent group vs. 2.0 (range 1.0–3.0) in BES group vs. 2.0 (range
.0–2.0) in TC stent group, p=NS] and in the internal elastic lam-
na (5.3±0.99mm2 in TCA stent group vs. 5.6±1.05mm2 in TCALA
tent group vs. 5.3±0.71mm2 in BES group vs. 5.0±0.68mm2 in
C stent group, p=NS) among the four groups. There were sig-
iﬁcant differences in the lumen area (2.7±1.0mm2 in TCA stent
roup vs. 2.7±1.24mm2 in TCALA stent group vs. 2.7±1.30mm2
n BES group vs. 1.7±0.63mm2 in TC stent group, p<0.001),
n the neointima area (2.6±0.94mm2 in TCA stent group vs.
.9±0.83mm2 in TCALA stent group vs. 2.6±1.06mm2 in BES
roup vs. 3.3±0.58mm2 in TC stent group, p<0.01), in the percent
rea stenosis (48.9±16.25% in TCA stent group vs. 53.5±17.19% in
CALA stent group vs. 50.1±23.20% in BES group vs. 60.2±10.12%
n TC stent group, p<0.001), in the ﬁbrin score [1.0 (range 0.0–3.0)
n TCA stent group vs. 1.0 (range 0.0–2.0) in TCALA stent group
s. 2.0 (range 1.0–3.0) in BES group vs. 0.5 (range 0.0–2.0) in TC
tent group, p<0.0001], and in the inﬂammation score [1.0 (range
.0–2.0) in TCA stent group vs. 1.0 (range 0.0–2.0) in TCALA stent
roup vs. 2.0 (range 1.0–3.0) in BES group vs. 1.0 (range 0.0–2.0) in
C stent group, p<0.0001] among the four groups (Fig. 4).logy 64 (2014) 409–418
Scanning electron microscopic analysis
SEM revealed complete stent strut coverage in all groups. There
was no signiﬁcant difference in strut coverage among the four stent
groups (Fig. 5).
Micro-computed tomography analysis
In-stent restenosis rateofM-CT showedsimilar resultswithper-
cent area stenosis in histopathologic analysis (51.3±15.2% in TCA
stent group vs. 51.8±10.6% in TCALA stent group vs. 46.0±12.7%
in BES group vs. 68.5±20.1% in TC stent group) (Fig. 6).
Discussion
Our study was conducted to compare the TCA (TiO2 ﬁlm-coated
stentwith abciximab) and TCALA (TiO2 ﬁlm-coated stentwith ALA)
with BES (biolimus A9-eluting stent with biodegradable polymer)
and TC (TiO2 ﬁlm-coated stent) in a porcine coronary restenosis
model. Our study showed that TCA and TCALA appeared to be
effective on inhibition of the neointimal proliferation and ﬁbrin
and inﬂammation scores were signiﬁcantly lower than BES. The
results demonstrated that the polymer that induces inﬂammation
anddelayed arterial healingwas not used in TiO2 ﬁlm-coated stent;
therefore, ﬁbrin and inﬂammation scores of TCA and TCALA are
signiﬁcantly lower than with a polymer-based drug delivery stent.
To measure the re-endothelialization, the stented coronary
tissues should have treated as methyl methacrylate or glycol
methacrylate block which is not remove stent strut. However, we
treated parafﬁn block. So, we were unable to measure the re-
endothelialization. We conducted IHC using CD31, CD34, and von
Willebrand factor for endothelium detection. However, the stent
strut extraction eliminated weak single layer endothelium. There-
fore, we found very rare ﬂuorescent positive cells in the specimen.
Baremetal stents can cause inﬂammatory reactions, which lead
to neointimal proliferation around the stent struts [22]. Titanium is
commonly used in biomedical materials for dental and orthopedic
devices because it has good blood compatibility, biochemical sta-
bility, and mechanical attributes. TiO2 ﬁlms have superior blood
compatibility compared to stainless steel, gold, and other stent
materials [23]. When TiO2 is coated on a bare metal stent, it
enhances anticoagulation effect and inhibits inﬂammatory reaction
[24]. So we covered with a TiO2 thin ﬁlm onto a cobalt–chromium
bare metal stent by the (PECVD) process. Then, abciximab and ALA
were grafted onto the modiﬁed TiO2 ﬁlm-coated stents through
covalent bonding without polymer [5].
Our previous study demonstrated that abciximab-coated stents
showed comparable inhibition of inﬂammatory cell inﬁltration
and neointimal hyperplasia with sirolimus-eluting stents and
paclitaxel-eluting stents in a porcine coronary restenosis model
[11]. And abciximab-coated stents signiﬁcantly inhibit neointima
hyperplasia in human coronary de novo lesions [10]. Moreover
abciximab-coated stents were safe and effective without stent
thrombosis in a prospective randomized trial of patientswith acute
myocardial infarction [25]. The possible mechanisms responsible
for inhibition of neointimal hyperplasia by abciximab might be
anti-platelet, anti-inﬂammatory, and anti-proliferative actions.
ALA is a potent anti-oxidant agent and is beneﬁcial for improv-
ing endothelial dysfunction [26]. And ALA is an effective agent
to reduce inﬂammatory processes [27]. Moreover, ALA prevents
neointimal hyperplasia and late stent thrombosis after angioplasty
or DES implantation [14,28]. In our previous study, ALA-coated
stents inhibited neointimal hyperplasia in the porcine coronary
restenosis model [15]. In our previous study using dual-coated
K.S. Lim et al. / Journal of Cardiology 64 (2014) 409–418 415
Fig. 4. Injury score (A), internal elastic lamina (B), lumen area (C), neointima area (D), % area stenosis (E), ﬁbrin score (F) and inﬂammation score (G), in TCA, TCALA, BES and
TC. A, F and G are expressed as median (interquartile range). TCA stent, TiO2 ﬁlm-coated stent with abciximab; TCALA stent, TiO2 ﬁlm-coated stent with alpha lipoic acid;
BES, biolimus A9-eluting stent with biodegradable polymer; TC stent, TiO2 ﬁlm-coated stent.
416 K.S. Lim et al. / Journal of Cardiology 64 (2014) 409–418
Fig. 5. Scanning electron microscopic analysis of the stent-implanted coronary arteries. TCA stent implanted (A: 100×), TCALA stent implanted (B: 100×), BES implanted
(C: 100×) and TC stent implanted (D: 100×). TCA stent, TiO2 ﬁlm-coated stent with abciximab; TCALA stent, TiO2 ﬁlm-coated stent with alpha lipoic acid; BES, biolimus
A9-eluting stent with biodegradable polymer; TC stent, TiO2 ﬁlm-coated stent.
Fig. 6. Micro-computed tomography (M-CT) of in-stent restenosis (ISR) with TCA, TCALA, BES, and TC. TCA stent, TiO2 ﬁlm-coated stent with abciximab; TCALA stent, TiO2
ﬁlm-coated stent with alpha lipoic acid; BES, biolimus A9-eluting stent with biodegradable polymer; TC stent, TiO2 ﬁlm-coated stent.
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tents with abciximab and ALA, the dual DES suppressed inﬂam-
atory reaction [29].
The BES with biodegradable polymer that was developed as
third generation DES elutes new-limus derivative biolimus A9
rom a bioabsorbable polylactic acid (PLA) polymer [30]. The poly-
ers are known to be related to restenosis, inﬂammation, and late
tent thrombosis. But BES releases biolimus A9 into the vessel wall
hile the PLApolymer is decomposed by contacted coronary artery
issues. Therefore, BES with bioabsorbable polymer signiﬁcantly
educes the risk of very late stent thrombosis compared to DES
ith durable polymer.
In our previous study using BES, BES appears to be reliable on
he inﬂammatory reaction at overlapping segments as well as non-
verlapping segments [31]. In clinical research, BES showeda lower
ate of the composite of major adverse cardiac events in patients
ith ST-segment elevation myocardial infarction undergoing pri-
ary percutaneous coronary intervention compared with a BMS
32].
TCA and TCALA showed a similar neointimal suppressive effect
ompared to commercial BES which used strong immunosuppres-
ive agents such as sirolimus derivatives in this experiment. TC
an replace BMS at the present time. We will attempt the clinical
pplication of TCA and TCALA after long-term follow-up experi-
ent usingminipigs. In our advanced research, the TC-based-limus
erivatives eluting stent (TCL) is under development.We think that
eveloping TCL can replace the conventional DES with polymer.
tudy limitations
Our study had some limitations. First, we used normal porcine
oronary arterieswithout atherosclerotic lesions unlike the human
linical situation with pre-existing atherosclerosis. Second, we
xamined inﬂammatory reaction based on H&E stain. IHC tech-
iques are the standard for such studies [33]. Third, we did not
erform long-term follow-up experiments such as over 6 months
sing minipigs.
onclusion
This study shows that TCA and TCALA are more effective to
educe neointimal hyperplasia compared to TC. Moreover, inhibi-
ion of neointimal proliferation of TCA and TCALA is not inferior
o commercial BES and ﬁbrin and inﬂammation scores are signiﬁ-
antly lower than with BES at 1 month after stenting in a porcine
oronary restenosis model.
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